Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD: Evidence from a retrospective cohort study

International Journal of Clinical Practice

Volumn 62, Issue 9, 2008, Pages 1373-1378

  Blamoun, A I ^a   Batty, G N ^b   DeBari, V A ^a   Rashid, A O ^a   Sheikh, M ^a   Khan, M A ^a  

^a SETON HALL UNIVERSITY   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PREVASTATIN; SIMVASTATIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE EXACERBATION; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RESPIRATORY TRACT INTUBATION; STATISTICAL SIGNIFICANCE;

ACUTE DISEASE; AGED; COHORT STUDIES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KAPLAN-MEIERS ESTIMATE; MALE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 49349115994     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2008.01731.x     Document Type: Article

References (28)

1. Hunninghake DB. Cardiovascular disease in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005 2: 44 9.
2. Watz H, Bitter-Suermann S, Kaniess F, Magnussen H. COPD-pharmakologische basisbehandlung und zukunft der antiinflammatorischen therapie. Med Klin 2006 101: 283 92.
3. Lee J-H, Lee D-S, Kim E-K et al. Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs. Am J Respir Crit Care Med 2005 172: 987 93.
4. Morimoto K, Janssen WJ, Fessler MB et al. Lovastatin enhances clearance of apoptotic cells (eferocytosis) with implications for chronic obstructive pulmonary disease. J Immunol 2006 176: 7657 65.
5. Mancini GBJ, Etmian M, Zhang B, Levesque LE, FitzGerald JM, Brophy JM. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin-receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 2006 47: 2554 60.
6. Soyseth V, Brekke PH, Smith P, Omland T. Statin use is associated with reduced mortality in COPD. Eur Respir J 2007 29: 279 83.
7. Global Initiative for Chronic Obstructive Lung Disease. A Collaborative Project of the National Heart, Lung, and Blood Institute, NIH (USA) and the World Health Organization. Global Initiative for Chronic Obstructive Lung Disease, 2006. http://www.goldcopd.com (accessed 12 March 2008).
8. Pearson ES, D'Agostino RB, Bowman LR. Tests for departure from normality: comparison of powers. Biometrika 1977 64: 231 46.
9. Randles RJ, Wolfe DA. Introduction to the Theory of Nonparametric Statistics. New York: John Wiley and Sons, 1979.
10. Lehmann EL. Nonparametrics: Statistical Methods Based on Ranks, Revised. Upper Saddle River, NJ: Prentice Hall, 1998.
11. Jayatilaka S, Shakov R, Eddi R, Bakaj G, Baddoura WJ, DeBari VA. Clostridium difficile infection in an urban medical center: five-year analysis of infection rates among adult admissions and association with proton pump inhibitors. Ann Clin Lab Sci 2007 37: 241 7.
12. Calverley PMA, Scott S. Is airway inflammation in chronic obstructive pulmonary disease (COPD) a risk factor for cardiovascular events? COPD 2006 3: 233 42.
13. Kardos P, Keenan J. Tackling COPD: a multicomponent disease driven by inflammation. Med Gen Med 2006 8: 54.
14. Heaney LG, Lindsay JT, McGarvey LPA. Inflammation in chronic obstructive pulmonary disease: implications for new treatment strategies. Curr Medicinal Chem 2007 14: 787 96.
15. Barnes PJ, Shapiro SD, Pauwels RA. Obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 2003 22: 672 88.
16. Bowler RP, Barnes PJ, Crapo JD. The role of oxidative stress in chronic obstructive pulmonary disease. COPD 2004 1: 255 77.
17. Churg A, Wang RD, Tai H et al. Macrophage metalloelastase mediates acute cigarette smoke-induced inflammation via tumor necrosis factor-alpha release. Am J Respir Crit Care Med 2003 167: 1083 9.
18. Gupta J, Chattopadhaya D, Bhadoria DP et al. T lymphocyte subset profile and serum alpha-1-antitrypsin in pathogenesis of chronic obstructive pulmonary disease. Clin Exp Immunol 2007 149: 463 9.
19. Burge PS, Calverly PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000 320: 1297 303.
20. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000 343: 1902 9.
21. Calverly PM, Anderson JA, Celli B et al. The TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007 356: 775 89.
22. Schonbeck U, Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as anti-inflammatory agents. Circulation 2004 109: II18 26.
23. Forrester JS, Libby P. The inflammation hypothesis and its potential relevance to statin therapy. Am J Cardiol 2007 99: 732 8.
24. Nickenig G. Should angiotensin II receptor blockers and statins be combined? Circulation 2004 110: 1013 20.
25. Friedrich EB, Clever YP, Wassmann S, Werner N, Böhm M, Nickenig G. Role of integrin-linked kinase in vascular smooth muscle cells: regulation by statins and angiotensin II. Biochem Biophys Res Commun 2006 349: 883 9.
26. Alexeeff SE, Litonjua AA, Sparrow D, Vokonas PS, Schwartz J. Statin use reduces decline in lung function. VA normative aging study. Am J Respir Crit Care Med 2007 176: 742 7.
27. Penning-van Beest FJA, Termorshuizen F, Goettsch WG, Klungel OH, Kastelein JJ, Herings RMC. Adherence to evidence-based statin guidelines reduces the risk of hospitalization for acute myocardial infarction by 40%: a cohort study. Eur Heart J 2007 28: 154 9.
28. Armitage J. The safety of statins in clinical practice. Lancet 2007 370: 1781 90.